Travis Steed
BofA Securities, Research Division

[Audio Gap] Analyst at Bank of America. Next up, we have Beta Bionics, Stephen Feider, Chief Financial Officer. And we have Blake, Investor Relations.

Travis Steed
BofA Securities, Research Division

So maybe to start out, you reported a strong Q1, revenue 2.5%. Maybe just high level kind of what trends you see in the quarter and kind of drove the beat versus expectations.

Stephen Feider
CFO, Treasurer & Secretary

Well, happy to be at the conference. Thanks for hosting us. Let me just say that. It's good to be up here with you. So the main tailwind that we have for our business that allowed us to outperform and what we're excited about is we're seeing more and more adoption in the pharmacy channel. And what the pharmacy -- so in the first quarter, we had a high 30s percentage of all of our new patients get reimbursed through that channel.

Why that's important is for people who are -- for patients who are considering purchasing a pump, the out-of-pocket that you see in pharmacy is something like $25 or less per month, whereas contrasting that to DME reimbursement -- the out-of-pocket is closer to something -- somewhere in the range of $500 to $1,500. So a dramatic difference in price, and that creates a much easier product for the patient to purchase better for Beta Bionics.

So number two is, we are expanding the field sales team. So we did an expansion in the first quarter of 2026. We are